April 25, 2014
Taiho Pharmaceutical announced on April 22 that its investigational novel anticancer agent ET-743 (trabectedin) met its primary endpoint of progression free survival (PFS) in a PII clinical trial in Japan. The study was conducted for malignant soft tissue sarcoma patients...read more